WO2007119684A1

WO2007119684A1 - Spraying agent

Info

Publication number: WO2007119684A1
Application number: PCT/JP2007/057661
Authority: WO
Inventors: Jun-Ichiro Arai; Mitsugu Yamashita
Original assignee: Daikin Industries, Ltd.
Priority date: 2006-04-13
Filing date: 2007-04-05
Publication date: 2007-10-25
Also published as: JP2007284363A

Abstract

Disclosed is a spraying agent for spraying into the air. The spraying agent comprises a solution of γ-aminobutyric acid (as a solute) dissolved in a solvent.

Description

Technical field

TECHNICAL FIELD [0001] The present invention relates to a propellant used for modifying an atmosphere such as a body space or an indoor space.

Various pharmacological actions have been confirmed for γ-aminobutyric acid (hereinafter referred to as “GABA”). Its pharmacological action is, for example, blood pressure regulation action that normalizes blood pressure, action that suppresses the increase of cholesterol and triglyceride in blood, action that activates the action of kidney, liver and spleen, and suppresses increase in blood glucose level Effects, activation of brain cell metabolism by improving the blood flow to the brain, anti-obesity effect, alcohol metabolism promoting effect, deodorizing effect such as body odor and bad breath, relieving emotional disorder and anxiety disorder It has the effect of improving the sequelae of stroke, the action of suppressing colon cancer, and the action of promoting growth hormone secretion. For this reason, GAB A has attracted much attention in recent years as a supplement.

[0003] In Patent Document 1, GABA is a type of amino acid that has become widely known in recent years due to the epidemic of germinated brown rice and the like, and is widely used in natural animals and plants from vegetables and fruits to fermented foods. It is one of the food ingredients that are usually ingested in our diet, and also has a very high medicinal effect. , Head weight, fatigue, hot flashes, tinnitus, memory problems, sleep disorders, decreased motivation) are disclosed.

[0004] Patent Document 2 discloses a sleep disorder composition containing a genus Valeriana or an extract thereof, a plant having a sedative action or an extract thereof, and GABA.

[0005] Patent Documents 3 to 5 disclose spraying a medicine in a room for the purpose of creating an indoor atmosphere suitable for sleep.

[0006] Patent Documents 6 to 8 disclose a spray and a spray device for the purpose of creating an indoor atmosphere suitable for sleep.

Patent Document 1: JP 2004-269361 A Patent Document 2: Japanese Patent Laid-Open No. 2003-183174

Patent Document 3: Japanese Patent Application Laid-Open No. 5-280784

Patent Document 4: Japanese Patent Laid-Open No. 2000-281585

Patent Document 5: Japanese Unexamined Patent Publication No. 7-96025

Patent Document 6: Special Table 2003-513719

Patent Document 7: International Publication No. 03Z047580 Pamphlet

Patent Document 8: Special Table 2003-522147

Disclosure of the invention

[0007] The purpose of the present application is to enable GABA to be taken into the body in a completely different manner.

[0008] The present invention is a propellant used to spray a space,

It is a solution in which GABA is dissolved as a solute in a solvent.

According to the present invention, GABA can be absorbed into the nasal mucosa and pulmonary by spraying the GABA solution into the space, and GABA can be taken into the body by a method other than oral. If GABA is continuously absorbed through the nasal mucosa and pulmonary, the blood concentration of GABA can be significantly increased compared to when GABA is taken orally.

[0010] Furthermore, since GABA also enters the lymph and does not cross the cerebrovascular barrier, GABA itself that is not an analog can be taken into the brain.

[0011] Furthermore, since GABA does not go through the portal vein, metabolism due to the first passage of the liver can be avoided.

[0012] In addition, if the GABA solution is sprayed during sleep, sleep can be introduced quickly.

It is possible to promote the secretion of growth hormone.

[0013] The spray of the present invention preferably has a GABA concentration of 0.0017-3.88 molZl.

0. 0097 to 1. 94 mol / l is preferred over the power! / ヽ.

[0014] The spray of the present invention may contain a surfactant such as an emulsifier for food additives such as sucrose fatty acid esters, and may further contain an alcohol such as ethanol.

[0015] The spray of the present invention may have a surface tension of 20 to 50 mNZm. Brief Description of Drawings

FIG. 1 is a schematic configuration diagram of an electrostatic spraying device (10).

FIG. 2 is a perspective view of a spray cartridge (15).

FIG. 3 is a cross-sectional view showing a main part of the spray cartridge (15).

[FIG. 4] (A) is a cross-sectional view illustrating the tip of the spray nozzle (31) during spraying, and (B) is a cross-sectional view illustrating the tip of the spray nozzle (31) while spraying is stopped.

FIG. 5 is a graph showing the relationship between time and blood GABA concentration.

FIG. 6 is a graph showing the relationship between the particle size of a solution sprayed by an ultrasonic nebulizer and its ratio.

FIG. 7 is a graph showing the relationship between the particle size of a solution and its ratio when sprayed with an ink jet spray device.

FIG. 8 is a graph showing the relationship between the particle size of a solution and its proportion when sprayed by an electrostatic atomizing spray device.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, embodiments will be described in detail.

[0018] (Spraying agent)

The propellant according to the present embodiment is a solution in which GABA is dissolved as a solute in a solvent, and the atmosphere is modified by spraying the space with a spray device or the like. Used for absorption into the human body by absorption

[0019] This propellant is a solution in which GABA is dissolved as a solute in a solvent as a basic component.

[0020] GABA is a compound represented by the following chemical formula. GABA is an inhibitory neurotransmitter present in high concentrations in the mammalian central nervous system, but can also be synthesized artificially. GABA, for example, regulates blood pressure to normalize, suppresses increases in cholesterol and triglycerides in blood, activates kidney, liver, and spleen, and increases blood sugar levels. An action that suppresses blood flow, activates brain cell metabolism by improving the blood flow to the brain, prevents obesity, promotes alcohol metabolism, deodorizes body odor and bad breath, and causes emotional and anxiety disorders Relieving action, stroke aftereffect improvement, large intestine Expected to have pharmacological actions such as cancer suppressive action and growth hormone secretion promoting action.

[0021] H NCH CH CH COOH

2 2 2 2

Examples of the solvent include water (including water for injection, physiological saline and Ringer's solution), alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like. And as a solvent, what mixed 1 type or 2 types or more among these is used.

[0022] The propellant preferably has a GABA concentration of 0.0017-3. 88 molZl.

More preferably, it is 94 molZl. If the concentration of GABA is within such a range, an appropriate amount of GABA can be taken into the body, and the viscosity and liquid properties of the soluble propellant will be appropriate. In addition, the usage mode is such that the spray amount per unit time is increased and the propellant is replenished in a short cycle (for example, 1 day), and the spray amount per unit time is decreased and the cycle is increased (for example, 2 to 3). It is possible to cope with deviations in usage patterns such as replenishing the propellant every month. In particular, if the GABA concentration is 0.0017-1.94 molZl, it is suitable for the usage form in which the spraying amount per unit time is increased and the propellant is replenished in a short cycle. In the spray agent dissolved in water of GABA as a solvent, the concentration of GABA 0. 0097~3. 88molZl corresponds to 0.1 to 40 weight ^_0/0, the concentration of GABA 0. 0,097 to 1. Ne th abutted to 94 mol / l strength SO. 1 to 20 weight ^_0/0.

[0023] Force that requires a large amount of energy for spraying when the surface tension of the propellant is high When using a spray device (applied voltage of around 5 kV) for normal home appliances, the surface tension of the propellant is about 30 mN. It is necessary to be. On the other hand, for example, the surface tension of a 20% GABA aqueous solution is about 75 mNZm (the surface tension of water is about 70 mNZm).

[0024] Accordingly, the propellant preferably has a surface tension of 20-50 mNZm, more preferably 25-35 mNZm! /.

[0025] Then, the propellant that realizes this may contain a surfactant. As surfactants, emulsifiers for food additives are preferred, for example, sucrose fatty acid ester, glycerin fatty acid ester, vegetable lecithin, egg yolk lecithin, vegetable sterol, sphingolipid, sorbitan fatty acid ester and sodium metaphosphate. It is done. As the surfactant, one or a mixture of two or more of these is used. World The content of the surfactant is preferably 0.01 to 1% by mass, and more preferably 0.05 to 0.2% by mass.

[0026] The spray may contain a lower alcohol in addition to the surfactant.

Thereby, the surface tension of the propellant can be lowered more effectively. The lower alcohol is a chain alcohol having 1 to 5 carbon atoms. Examples of the lower alcohol include ethanol, isopropanol, and ethylene glycol. And as alcohol, what mixed 1 type or 2 types or more among these is used. The content of alcohol is preferably 1 to 40% by mass, more preferably 10 to 30% by mass.

[0027] In addition to this, the spray may contain a conductivity adjusting agent, a solubilizing agent, a suspending agent, a tonicity agent, a buffering agent, a soothing agent, and the like. Further, it may contain formulation additives such as preservatives, anti-acid additives, coloring agents, sweetening agents, and fragrances.

[0028] Examples of the conductivity adjusting agent include ethanol, isopropanol and the like. As the conductivity adjusting agent, one or a mixture of two or more of these is used.

[0029] Examples of solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, isopropanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate. , Sodium acetate and the like. As a solubilizing agent, one or a mixture of two or more of these is used.

[0030] Examples of the suspending agent include stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalcoyl chloride, benzethonium chloride, and a surfactant (for example, glyceryl monostearate). , Hydrophilic polymers (for example, polyvinyl alcohol, polybutylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethenoresenorelose, hydroxyethinoresenorelose, hydroxypropinolecellulose, etc.), polysorbates, polyoxyethylene hydrogenated castor oil Etc. Examples of the tonicity agent include sodium chloride salt, glycerin, D-mannitol, D-sorbitol, glucose and the like. As a suspending agent, one or more of these are mixed. The combined one is used.

[0031] Examples of the buffer include buffer solutions of phosphate, acetate, carbonate, citrate, and the like. As the buffer, one or a mixture of two or more of these is used.

[0032] Examples of the soothing agent include benzyl alcohol. As the soothing agent, one or a mixture of two or more is used.

[0033] Examples of the preservative include noraoxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like. And as a preservative, what mixed 1 type, or 2 or more types of these is used.

[0034] Examples of the antioxidant include sulfite and ascorbate. And as an antioxidant, what mixed 1 type, or 2 or more types of these is used.

[0035] Examples of the colorant include edible red No. 2 or 3, edible yellow No. 4 or 5, edible blue No. 1 or! Insoluble lake pigments such as aluminum salts of water-soluble edible tar pigments, natural pigments such as 13-strength rotin, chlorophyll, and bengara. As the colorant, one or a mixture of two or more of these is used.

[0036] Examples of the sweetening agent include saccharin sodium, dipotassium glycyrrhizin, aspartame, stevia and the like. And as a sweetener, what mixed 1 type or 2 or more types of these is used.

[0037] Examples of the fragrances include water-soluble essences for lemon, lavender or cypress scents. And as a fragrance | flavor, what mixed 1 type, or 2 or more types of these is used.

[0038] The propellant preferably has a conductivity of 50 to: LOOO μs Zcm, more preferably 100 to 300 μs Zcm. If the electrical conductivity is in this range, the spray state is stable and large particles are not generated, so it is possible to suppress particle adhesion to the tip of the circular spray nozzle of the spray device, which is one of the causes of clogging. it can. In order to reduce the electrical conductivity, it is necessary to increase the ratio of petroleum oil added. The upper limit is set by the Fire Service Act, and the above range is preferable to comply with this. [0039] The propellant preferably has a viscosity of 0.1 to 5. lcP, more preferably 0.1 to 3. OcP. When the viscosity is within such a range, troubles such as clogging of the spraying device are unlikely to occur. This value shows that when spraying with a 0.4-0. 6 mm circular spray nozzle, spraying is possible by increasing the applied voltage or increasing the conductivity even if the viscosity is high.

[0040] If such a spray is used, GABA can be absorbed into the nasal mucosa and pulmonary by spraying it into the space, and GABA can be obtained by a method other than oral, without taking a tablet. Can be taken into the body. Then, as will be shown later in the Examples, if GABA is continuously absorbed through nasal mucosa or pulmonary, the blood concentration of GABA can be significantly increased as compared with the case where GABA is taken orally.

[0041] Since GABA also enters the lymph and does not pass through the cerebrovascular barrier, GABA itself that is not an analog can be taken into the brain.

[0042] Furthermore, since GABA does not go through the portal vein, metabolism due to the first passage of the liver can be avoided.

[0043] If spraying is performed during sleep, sleep can be promptly introduced and growth hormone secretion can be promoted.

[0044] Note that the particle size of the solution is sufficiently small in spraying of the propellant! Since it is easier to enter the nose and lungs and the absorption is smooth, it is preferable to spray the solution with a particle size of 10 m or less, more preferably 5 m or less. . Also, the intake of an appropriate amount of GABA in the body, it is preferable to the concentration of GABA in the space 10 gZm ^³ ~100mgZm ³ by spraying. The maximum intake of GABA into the body is about lOOOmg per day, and when spraying the spray into the indoor space, it is only necessary to spray about 10g of spray per day in terms of GABA.

[0045] The spraying device used for spraying the propellant is provided, for example, in a nebulizer for inhaling a chemical solution that sprays the propellant into the human body space, and an air conditioner that sprays the propellant into the indoor space. Sprayer and the like. Examples of the spraying method of the spraying device include an ultrasonic method, a bubble jet (registered trademark) method, a piezo method, and an electrostatic atomization method.

[0046] (spraying device) Next, an electrostatic spraying device that sprays the spray will be described.

[0047] <Device configuration>

1 to 3 show the configuration of the electrostatic spraying device (10).

[0048] The electrostatic spraying device (10) includes a spray cartridge (15), a power source (16), and a control unit (17).

[0049] The spray cartridge (15) includes a solution tank (20), a nose, a nose unit (30), an electrode holder (40), and a ring electrode (35).

[0050] The solution tank (20) includes a hollow tank body (21) having an air vent hole (25) formed in the top plate. Near the lower end of the front surface of the tank body (21), a pipe portion (23) protruding in the horizontal direction is provided. The pipe part (23) communicates with the tank body (21) through a through hole (24) formed in the front wall of the tank body (21).

[0051] The nozzle unit (30) includes a circular spray nozzle (31) having an inner diameter of, for example, 0.4 to 0.6 mm, and a cylindrical bottomed cap-shaped nozzle holder (32). The nozzle holder (32) is provided so as to cover the pipe portion (23). The spray nozzle (31) has its base end inserted into the center of the bottom of the nozzle holder (32), thereby leading to the tank body (21) via the pipe (23) and the through hole (24). Yes. The nozzle holder (32) is provided with a terminal portion (33) formed so as to extend from the outer periphery to the side. The nozzle holder (32) and the terminal part (33) are constituted by electrodes formed of conductive grease, and the spray nozzle (31) is electrically connected thereto.

[0052] The electrode holder (40) is concentrically provided with an interval between the inner cylindrical portions that are concentrically coupled to each other on the proximal end side.

(41) and outer cylinder (42). The electrode holder (40) is provided so that the inner cylinder (41) fits into the nozzle holder (32)! / The electrode holder (40) has a ring electrode formed in an annular shape with a terminal portion (36) formed of a tongue protruding laterally on the outer peripheral edge on the distal end side of the outer tube portion (42). It is fitted.

The power source (16) is a direct current high voltage power source. This power source (16) is connected to the spray nozzle (31) via the terminal part (33) of the positive terminal force squel holder (32), and the grounded negative terminal is connected to the terminal part of the ring electrode (35). (36) are electrically connected to each other.

[0054] The control unit (17) is configured to perform on / off switching control of the power source (16). Yes.

[0055] It should be noted that since the viscosity of the propellant stored in the tank main body (21) increases and the spray nozzle (31) may be clogged when the environmental temperature is lowered, a heat insulating material is provided to the tank main body (21). A heat insulating mechanism such as providing a heater may be configured, or a heating mechanism such as a surface heater may be attached.

[0056] <Spray operation>

The spraying operation of the spray using the electrostatic spraying device (10) will be described.

[0057] In the electrostatic spraying device (10), the above-mentioned spraying agent is stored in the tank body (21) of the solution tank (20).

[0058] The position of the liquid level (51) in the tank body (21) is higher than the tip of the spray nozzle (31). The liquid level (51) in the tank body (21) and the tip of the spray nozzle (31) Since there is a head difference between them, the spray in the tank body (21) is supplied to the tip of the spray nozzle (31).

[0059] When the power source (16) is turned on, a potential difference of, for example, about 3 to 7 kV is applied between the spray nozzle (31) and the ring electrode (35), and the vicinity of the tip of the spray nozzle (31). An electric field is formed. Further, the propellant in the spray nozzle (31) is polarized, and + (plus) charges are collected near the gas-liquid interface (52) at the tip of the spray nozzle (31). At the tip of the spray nozzle (31), as shown in FIG. 4 (a), the gas-liquid interface (52) is extended into a conical shape, and the conical gas-liquid interface (52) Top force Part of the propellant is torn into droplets and supplied to the interior space. The occupant inhales the propellant droplets with the air as they breathe. In order for the droplets contained in the inhalation to reach the alveoli of the occupants, the droplet size is preferably as small as 10 m or less, more preferably 5 μm or less.

[0060] When the power source (16) is turned off, the spray nozzle (31) and the ring electrode (35) have the same potential, and the gas-liquid interface (52) formed at the tip of the spray nozzle (31) As shown in FIG. 4 (b), since the surface tension and the hydraulic pressure due to the head difference are balanced, the aqueous solution does not flow out from the tip of the spray nozzle (31). Specifically, even when a liquid pressure of, for example, 20 mmH 2 O acts on the gas-liquid interface (52) at the tip of the spray nozzle (31), the aqueous solution (50

2

) Leakage is prevented.

[0061] <Operation control>

The operation control by the control unit (17) of the electrostatic spraying device (10) will be described. [0062] In this electrostatic spraying device (10), the control unit (17) is configured to turn on the power source (16) (on time) and turn off the power source (16) (off time). The operation of spraying the propellant is controlled by controlling the duty ratio.

[0063] Specifically, in this electrostatic spraying device (10), the duty ratio is set higher at the start of spraying than at the time of steady spraying. It is controlled so that the spray amount per unit time becomes higher. As a result, the concentration of GABA in the space can be increased in a short time with the spray start force.

[0064] Further, in this electrostatic spraying device (10), during steady spraying, the pressure applied to the propellant loaded by the spray nozzle (31) depends on the height of the liquid surface (51) in the solution tank (20). The duty ratio is set according to the height of the liquid level (51) (the higher the liquid level (51), the lower the duty ratio), so that the GABA concentration in the space becomes constant. Controlled. Thereby, the intake of GABA into the body can be performed stably and continuously.

[0065] <Agitating operation control>

Control of the propellant stirring operation by the control unit (17) will be described.

[0066] At the tip of the spray nozzle (31), if the spraying of the solvent from the propellant, selective electric field attraction of the solvent, or the formation of a concentration gradient due to the difference in momentum between GABA and the solvent occurs, the viscosity of the propellant An ascent may occur, which may cause clogging of the spray nozzle (31). In this electrostatic spraying device (10), the power is supplied for a predetermined time (for example, 5 to 20 seconds) at regular intervals (for example, every 1 to 10 minutes) during spraying or stopping of the propellant. Control is made to repeat the formation and extinction of the electric field by repeating ON and OFF of (16) (for example, repetition frequency of 0.1 to: LO. OHz). When the power supply (16) is turned on and an electric field is formed, the spray agent gradually swells at the tip of the spray nozzle (31), while when the power supply (16) is turned off and the electric field disappears. The propellant swelled due to the tip force of the spray nozzle (31) is retracted into the spray nozzle (31). By repeating the formation and extinction of this electric field, the propellant repeats the behavior of exiting and retracting against the spray nozzle (31), and is agitated by this movement. As a result, it is possible to suppress an increase in the concentration of the propellant at the tip of the spray nozzle (31).

[0067] <Operation control during sleep mode> The sleep operation mode operation control by the control unit (17) will be described.

[0068] In the electrostatic spraying device (10), when the sleep operation mode is selected, a sleep onset detection sensor (not shown) connected to the control unit (17) detects sleep on the person, Control is performed so that spraying of the propellant is started after a certain period of time has elapsed since detection (for example, after 1 hour). Since GABA A intake efficiency is highest after a certain period of sleepiness, it can effectively promote growth hormone secretion.

[0069] It should be noted that an optimal spray amount may be set based on the gender of the sleeper and the input of Z or weight and Z or age.

[0070] [Example]

(Test evaluation 1)

For each of subjects A, B, and C, the GABA concentration of GABA in the subject's blood is different between when nasal mucosal absorption and pulmonary absorption are administered by spraying GABA, and when GABA is orally administered. The change with time was examined.

The GABA spray administration test was performed by spraying 500 μL of a 20% GABA aqueous solution spray (GABA 100 mg) in the vicinity of the subject's face with a nebulizer (a spraying device). Spraying was continued for 30 minutes starting from the start of spraying. At this time, the spray was sprayed so as to have a particle size of about 1 Onm. The subjects were voted at the start, 10 minutes, and 30 minutes, respectively, and the blood GABA concentration was analyzed.

[0072] The test for oral administration of GABA was conducted by giving a subject a 500 μL of a 20% GABA aqueous solution spray (GABA 100 mg). Then, when the subject started drinking, the subjects were voted at the start, 10 minutes, 30 minutes, and 60 minutes, respectively, and the GABA concentration in the blood was analyzed.

[0073] Table 1 shows the test results.

[0074] [Table 1] Start time 1 0 minutes 30 minutes 60 minutes Subject A 3. 1 4 1 0. 5 0 1 6. 9 0 One fog subject B 1. 9 9 5. 3 5 1 2. 2 0 ― Throw subject C 2 4 5 2. 4 5 2. 5 2-Average 2.5 2.5 3 6. 1 0 1 0. 5 4-

Standard deviation 0.5 8 4 .0 8 7 .3 3-Trans-subject A 1 .9 7 2 .9 9 3 .3 3 2 .7 6 Subject B 2 .2 1 1 .6 7 2 .1 9 1. 5 5 Throwing subjects C 1 .6 1 2 .1 6 2 .2 8 2 .0 7 Average 1.9 3 2 .2 7 2 .6 0 2 .1 3 Standard deviation 0 .3 0 0 .6 7 0 . 6 3 0. 6 1 Position: μ g / d 1

[0075] FIG. 5 shows the relationship between the time and the average of the GABA concentrations in the blood of three people for each of GABA spray administration and GABA oral administration.

[0076] According to these, when GABA was administered by spraying, the blood concentration of GABA increased dramatically with time, whereas when administered orally, the blood concentration of GABA almost changed. I can't see. This is because when GABA is taken orally, most of it is absorbed and metabolized before it is contained in the blood, whereas GABA is sprayed to absorb nasal mucosa and pulmonary absorption. This is thought to be because GABA is absorbed without being metabolized and contained in blood.

[0077] (Test evaluation 2)

20% GABA aqueous solution (spray 1), 0.1% by weight sucrose fatty acid ester as a surfactant 20% GABA aqueous solution (spray 2), 1 sucrose fatty acid ester as a surfactant 20% by weight aqueous solution of GABA containing 5% by weight (spraying agent 3) and 20% by weight aqueous solution of GABA containing 0.1% by weight of sucrose fatty acid ester as a surfactant and 20% by weight of ethanol (spraying) When the surface tension of each of the sprays 4) was adjusted and measured, the spray 1 was about 75mNZm, the spray 2 was about 38mNZm, the spray 3 was about 38mNZm, and the spray 4 was about 30mNZm. [0078] From these results, it can be seen that the surface tension of the propellant can be lowered by containing a surfactant, but the effect is limited even if the concentration is increased. On the other hand, it can be seen that the surface tension of the propellant can be further reduced by adding ethanol in addition to the surfactant.

[0079] (Test Evaluation 3)

Spraying a 10% by weight aqueous solution of GABA with an ultrasonic nebulizer, an inkjet spraying device, and an electrostatic atomization spraying device, and measuring the particle size distribution of the solution at that time with a QCM cascade impactor and Measurements were made using a DMA (differential mobility analyzer). The measurement was carried out at a location 2 to 3 cm from the spray nozzle.

[0080] Fig. 6 is an ultrasonic nebulizer, Fig. 7 is an ink jet type spraying device, and Fig. 8 is a relationship between the particle size of the solution and its ratio when sprayed by an electrostatic atomizing type spraying device. Indicates. Figures 6 and 7 show the measurement results with the QCM cascade impactor, and Figure 8 shows the measurement results with DMA.

[0081] According to these figures, in the spraying by the ultrasonic nebulizer and the ink jet spraying device, the particle size of the solution is almost 25 m, which is relatively large, whereas the spraying by the electrostatic atomization method is used. When spraying with a device, it can be seen that most of the particle size of the solution is 1 μm or less, which is smaller than that of other methods. For transpulmonary absorption, the particle size reaching the alveoli is 1-2 μm, and the optimal particle size is said to be 0.1 μm. Therefore, in this embodiment, it is better to use an electrostatic atomization type spraying device.

Industrial applicability

[0082] The present invention is useful for a propellant used for modifying the atmosphere of a body space or an indoor space.

Claims

The scope of the claims

[1] A propellant used to spray a space,

A spray comprising a solution in which aminoaminobutyric acid is dissolved as a solute in a solvent.

[2] The propellant according to claim 1, wherein

A propellant, characterized in that the concentration of γ-aminobutyric acid is 0.0017 to 3.88 molZl.

[3] In the propellant according to claim 2,

A propellant characterized in that the concentration of γ-aminobutyric acid is 0.0001 to 1.94 molZl.

[4] The propellant according to claim 1, wherein

A propellant comprising a surfactant.

[5] The propellant according to claim 4,

The surfactant is an emulsifier for food additives.

[6] In the propellant according to claim 5,

The surfactant is one or more selected from sucrose fatty acid ester, glycerin fatty acid ester, plant lecithin, egg yolk lecithin, plant sterol, sphingolipid, sorbitan fatty acid ester and sodium metaphosphate. Propellant.

[7] In the propellant according to claim 4,

A propellant further comprising a lower alcohol.

[8] In the propellant according to claim 7,

The propellant, wherein the lower alcohol is one or more selected from ethanol, isopropanol and ethylene glycol.

[9] In the propellant according to claim 4,

A propellant characterized by a surface tension of 20 to 50 mNZm.